David Moatazedi

David Moatazedi

CEO, President, Evolus

WHY: Nearly $500M-valued company has one of the first neurotoxins that competes with Botox on the commercial market. Previously at Allergan for 14 years as senior VP of Medical Aesthetics division.

Get the latest OC business updates for FREE

RECENT: Initial product Jeuveau, designed to act similarly to Botox but at a lower cost in treating moderate to severe frown lines, got FDA approval in February; had sales kick off in late June.

NOTABLE: Evolus is indirectly involved in a lawsuit with Allergan due to Korean manufacturer of its products, Allergan claims intellectual infringement.

FUN FACTS: Three kids: Sienna, Gavin, and Pierce; favorite book, “Pillars of the Earth.”

Return to List